[Management of Acute Coronary Syndrome : ESC Guidelines 2023]

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2023 Nov 30

PMID 38032511

Authors

Maria Buske

Hans-Josef Feistritzer

Alexander Jobs

Holger Thiele

Affiliations

Soon will be listed here.

Abstract

The new guidelines of the European Society of Cardiology (ESC) on the management of acute coronary syndrome (ACS) in 2023 encompass updates for both the guidelines pertaining to ST elevation myocardial infarction (STEMI) and acute coronary syndrome without ST segment elevation (NSTE-ACS). The previously separated guidelines from 2017 and 2020 were therefore revised and summarized. These guidelines address various topics, including diagnostics, acute management, antithrombotic treatment, out-of-hospital cardiac arrest, cardiogenic shock, invasive strategies, and long-term treatment. The notable updates compared to earlier guidelines address the recommendation regarding the timing of invasive diagnostics in NSTE-ACS (Non-ST elevation acute coronary syndrome), the procedure of revascularization in multivessel coronary artery disease and alternative regimens for antithrombotic treatment in patients with a high risk of bleeding.

References

Byrne R, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A . 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191. View

Thygesen K, Alpert J, Jaffe A, Chaitman B, Bax J, Morrow D . Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018; 138(20):e618-e651. DOI: 10.1161/CIR.0000000000000617. View

Chew D, Lambrakis K, Blyth A, Seshadri A, Edmonds M, Briffa T . A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT). Circulation. 2019; 140(19):1543-1556. DOI: 10.1161/CIRCULATIONAHA.119.042891. View

Stoyanov K, Hund H, Biener M, Gandowitz J, Riedle C, Lohr J . RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019; 9(1):39-51. PMC: 7008552. DOI: 10.1177/2048872619861911. View

Twerenbold R, Costabel J, Nestelberger T, Campos R, Wussler D, Arbucci R . Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction. J Am Coll Cardiol. 2019; 74(4):483-494. DOI: 10.1016/j.jacc.2019.05.046. View

Kite T, Kurmani S, Bountziouka V, Cooper N, Lock S, Gale C . Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J. 2022; 43(33):3148-3161. PMC: 9433309. DOI: 10.1093/eurheartj/ehac213. View

Jobs A, Mehta S, Montalescot G, Vicaut E, Vant Hof A, Badings E . Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. Lancet. 2017; 390(10096):737-746. DOI: 10.1016/S0140-6736(17)31490-3. View

Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20):2001-15. DOI: 10.1056/NEJMoa0706482. View

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

10.

Schupke S, Neumann F, Menichelli M, Mayer K, Bernlochner I, Wohrle J . Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16):1524-1534. DOI: 10.1056/NEJMoa1908973. View

11.

Koul S, Smith J, Gotberg M, Omerovic E, Alfredsson J, Venetsanos D . No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2018; 11(3):e005528. DOI: 10.1161/CIRCINTERVENTIONS.117.005528. View

12.

Montalescot G, van t Hof A, Lapostolle F, Silvain J, Lassen J, Bolognese L . Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014; 371(11):1016-27. DOI: 10.1056/NEJMoa1407024. View

13.

Tarantini G, Mojoli M, Varbella F, Caporale R, Rigattieri S, Ando G . Timing of Oral P2Y Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol. 2020; 76(21):2450-2459. DOI: 10.1016/j.jacc.2020.08.053. View

14.

Palmerini T, Della Riva D, Benedetto U, Reggiani L, Feres F, Abizaid A . Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017; 38(14):1034-1043. PMC: 5837418. DOI: 10.1093/eurheartj/ehw627. View

15.

Hahn J, Song Y, Oh J, Cho D, Lee J, Doh J . 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018; 391(10127):1274-1284. DOI: 10.1016/S0140-6736(18)30493-8. View

16.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V . Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018; 363:k3793. PMC: 6167608. DOI: 10.1136/bmj.k3793. View

17.

De Luca G, Damen S, Camaro C, Benit E, Verdoia M, Rasoul S . Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention. 2019; 15(11):e990-e998. DOI: 10.4244/EIJ-D-19-00539. View

18.

Hahn J, Song Y, Oh J, Chun W, Park Y, Jang W . Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019; 321(24):2428-2437. PMC: 6593635. DOI: 10.1001/jama.2019.8146. View

19.

Mehran R, Baber U, Sharma S, Cohen D, Angiolillo D, Briguori C . Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019; 381(21):2032-2042. DOI: 10.1056/NEJMoa1908419. View

20.

Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T . Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019; 321(24):2414-2427. PMC: 6593641. DOI: 10.1001/jama.2019.8145. View